Leukemia Clinical Trials

A listing of Leukemia medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 415 clinical trials
Featured trial
A Study Evaluating Safety and Tolerability and Pharmacokinetics of Navitoclax Monotherapy and in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasm

neoplasm (MPN) or chronic myelomonocytic leukemia (CMML).

essential thrombocythemia
polycythemia vera
stem cell transplantation
chronic myelomonocytic leukemia
ruxolitinib
  • 45 views
  • 12 May, 2022
  • 36 locations
Featured trial
An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis

The purpose of this study is to evaluate the efficacy and safety of itacitinib combined with low-dose ruxolitinib or itacitinib alone in subjects with myelofibrosis.   This is an open-label Phase 2 study with 2 cohorts: Cohort A: Itacitinib plus ruxolitinib  Drug: Itacitinib self-administered orally once daily at the   protocol-defined …

myelofibrosis
leukemia
myeloproliferative disorders
  • 172 views
  • 10 May, 2022
  • 9 locations
Featured trial
A Phase 1/2 Open-Label, Multicenter Study of INCB000928 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Anemia Due to Myeloproliferative Disorders

This is an open-label, nonrandomized, Phase 1/2 study to evaluate the safety and tolerability, the PK, the PD, and the efficacy (antianemic activity) of INCB000928 administered alone or in combination with ruxolitinib in participants with MF who are transfusion-dependent or presenting with symptomatic anemia. INCB000928 tablets will be administered orally …

anemia
  • 81 views
  • 10 May, 2022
  • 2 locations
Study of Biomarker-Based Treatment of Acute Myeloid Leukemia

-M1)." The specific subtype of acute myeloid leukemia will determine which sub-study, within this protocol, a participant will be assigned to evaluate investigational therapies or combinations with

  • 44 views
  • 22 Apr, 2022
  • 17 locations
A Study of Subcutaneous Blinatumomab Administration in Acute Lymphoblastic Leukemia (ALL) Patients

The study aims to evaluate the safety and tolerability of subcutaneous (SC) blinatumomab for treatment of Acute Lymphoblastic Leukemia (ALL) and to determine the maximum tolerated dose (MTD

  • 0 views
  • 01 May, 2022
  • 19 locations
Study to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid Leukemia

The aim of this study is to support development of asciminib in the pediatric population (1 to <18 years) previously treated with one or more TKIs. Full extrapolation of the efficacy of asciminib from adult to pediatric patients will be conducted. Full extrapolation is based on the concept that CML …

basophils
asciminib
leukemia
  • 0 views
  • 10 May, 2022
  • 16 locations
Optimization of TKIs Treatment and Quality of Life in Ph+ CML Patients ≥60 Years in Deep Molecular Response

In this phase III clinical randomized study, "fixed" intermittent administration (one month ON/one month OFF) of TKIs (control arm), will be compared with "progressive" intermittent administration (one month ON/one month OFF for the 1st year; one month ON/two months OFF for the 2nd year; one month ON/three months OFF for …

kinase inhibitor
tasigna
dasatinib
gleevec
imatinib
  • 3 views
  • 01 May, 2022
  • 1 location
Stopping Tyrosine Kinase Inhibitors in Affecting Treatment-Free Remission in Patients With Chronic Phase Chronic Myeloid Leukemia

This phase II trial studies how stopping tyrosine kinase inhibitors will affect treatment-free remission in patients with chronic myeloid leukemia in chronic phase. When the level of disease is

  • 2 views
  • 15 May, 2022
  • 83 locations
Siltuximab in Large Granular Lymphocytic Leukemia (LGLL)

The purpose of the study is to evaluate the safety and effectiveness of siltuximab for participants being treated for large granular lymphocytic leukemia (LGLL).

  • 0 views
  • 26 Apr, 2022
  • 1 location
CC-486 and Venetoclax for Acute Myeloid Leukemia

This is an open label, dose escalation Phase I single institution pilot study for relapsed and refractory AML patients using CC-486 (oral azacitidine) with venetoclax. At the completion of dose escalation and after establishment of the MTD or recommended dose of CC-486 with venetoclax, an expansion phase will commence, using …

  • 0 views
  • 20 Apr, 2022
  • 1 location